In Reply: Discharge Pack Study
We welcome the opportunity to clarify the five issues raised by Mr Gelardi. First, Mr Gelardi implies that the 18-day difference in exclusive breast-feeding duration between women receiving the commercial compared with those receiving the research discharge pack, although statistically significant, is not clinically relevant. The study only followed up women for 122 days; this difference represents 15% of the follow-up period. Because the protective effects of breast-feeding against allergens and infective agents are greatest in the first few weeks of life, we would argue that a 15% extension of the duration of exclusive breast-feeding during that period is clinically beneficial.
Keyword(s):
2012 ◽
Vol 109
(6)
◽
pp. 1154-1161
◽
Keyword(s):
2003 ◽
Vol 88
(9)
◽
pp. 778-783
◽
2020 ◽
Keyword(s):
2012 ◽
Vol 109
(3)
◽
pp. 564-571
◽
2009 ◽
Vol 13
(2)
◽
pp. 201-207
◽
2017 ◽
Vol 20
(14)
◽
pp. 2537-2548
◽
Keyword(s):
Keyword(s):